Search
Coral snake (micrurus fulvius) immune globulin antivenin (equine)
go.drugbank.com/drugs/DB13883ApprovedIt is intravenously administered so that the antivenin binds to and neutralizes coral snake venom. … Prior to lyophilization, the product contains 0.25% phenol and 0.005% thiomerosal (mercury derivative) [FDA Label].
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedUpon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function [ … bone marrow transplant setting, which may be due to "naive" nature of lymphocytes [A32223].
Iopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigationalMultiple myeloma is a malignancy involving the plasma cells of the bone marrow. … [L40739] Re-infusion of these modified T-cells leads to the targeted elimination of malignant plasma cells, on which BCMA is highly expressed.
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalanti-tumor immune response that would typically attempt to destroy the cancerous cells. … [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … [A216163] Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill cancer cells, and are infused back into the patient.
Categories: Genetically-modified Autologous T CellsSynonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. … [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic
Palovarotene
go.drugbank.com/drugs/DB05467Approved) demonstrating the greatest efficacy. … [L40010] On August 16, 2023, palovarotene was also approved by the FDA for the management of HO associated with FOP.[L47845]
Azatadine
go.drugbank.com/drugs/DB00719ApprovedWithdrawnThe antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury … Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]